Skip to main content

Harpoon Therapeutics, Inc.

HARPDelisted Mar 11, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001708493

Harpoon Therapeutics, Inc. was delisted on Mar 11, 2024; its insiders filed their last Form 4 on Mar 11, 2024; 41 institutions reported holding it in 13F filings for Q4 2023, worth $175.5M in total; no superinvestor held it.

Q1 2022 vs. Q4 2021

How the institutions holding Harpoon Therapeutics, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of HARP: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders8479−5
Shares26.0M25.4M−617.8K (−2.4%)
Value$196.3M$128.2M−$68.1M (−34.7%)

New holders (14)

Institutions that held Harpoon Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to HARP in Q1 2022
InstitutionSharesValue% of portfolio
Acuta Capital Partners, LLC497,500$2.47M1.18%
Tekla Capital Management LLC259,910$1.29M0.05%
State of Wisconsin Investment Board102,400$509.0K0.00%
Bridgeway Capital Management, LLC96,261$478.0K0.01%
FMR LLC66,798$332.0K0.00%
Corton Capital Inc.16,717$83.0K0.04%
Sequoia Financial Advisors, LLC13,200$66.0K0.00%
Delphia (USA) Inc.11,506$57.0K0.04%
ExodusPoint Capital Management, LP10,809$54.0K0.00%
Amalgamated Bank3,045$15.0K0.00%
Amalgamated Financial Corp.3,045$15.0K0.00%
Nisa Investment Advisors, LLC2,000$10.0K0.00%
Federation des caisses Desjardins du Quebec2,000$9.94K0.00%
The PNC Financial Services Group, Inc.332$2.00K0.00%

Sold out (19)

Institutions that held Harpoon Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.